{
  "docId": "019de074-0cc8-70d5-8924-3a1b552a09af",
  "docSlug": "77b0d3b8437e31981ed49d98afb5005f",
  "documentTitle": "OmniAb | Investor Conference Presentation Deck | 43 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 43,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Slide 41 of a presentation deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-0cc8-70d5-8924-3a1b552a09af/41",
  "deckHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af",
  "deckJsonHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af.json",
  "deckAnchorHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.09,
        "x": 0.9,
        "y": 0.92
      },
      "kind": "image",
      "text": "OmniAb logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a56eefc-f857-4db3-8ddf-09c2d0aa230b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.33,
        "x": 0.58,
        "y": 0.02
      },
      "kind": "image",
      "text": "GloriaBio and Arcus Biosciences logos",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "deafc464-e301-4d07-9d3a-936b0c1f9dda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.23,
        "w": 0.92,
        "x": 0.04,
        "y": 0.37
      },
      "kind": "list",
      "text": "In 2015, GloriaBio contracted with WuXi Biologics to discover and develop zimberelimab in China, using OmniRat. Zimberelimab entered clinic in March 2017, and NDA was submitted to China NMPA in February 2020. GloriaBio is also conducting trials in advanced solid tumors, and was granted Breakthrough Therapy designation for the treatment of patients with recurrent/metastatic cervical cancer.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85816ade-00d2-4dff-b3ed-e184a89a75dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.92,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "list",
      "text": "In August of 2021, zimberelimab (GLS-010), an OmniAb-derived fully human anti-PD-1 mAb, was approved in China for the treatment of recurrent or refractory classical Hodgkin’s lymphoma. Marked the first approval of an OmniAb-derived mAb.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f0209e9-b48a-4d67-9a5a-ccc03abdb28f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.62
      },
      "kind": "list",
      "text": "Zimberelimab is being developed by Arcus Biosciences (in collaboration with Gilead) in North America, Europe, Japan and certain other territories through a 2017 agreement. Arcus is conducting Phase 2 and 3 clinical trials investigating zimberelimab as part of combination therapy in lung, prostate, colorectal, pancreatic and GI cancers.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c15f8013-647d-4ec1-ad1d-e0e3010b2d23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.26,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Zimberelimab",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "032b8758-e917-4641-8dd2-8b7c637d361f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.53,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "THE FIRST APPROVED OMNIRAT-DERIVED ANTIBODY",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f18ffea4-8801-4d26-b1bd-13bbe8e90ab0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}